Evaluating a new implantable glucose monitoring device for diabetes

Early Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose Sensor in Adults with Diabetes Mellitus

This study is testing a new implantable device that continuously monitors blood sugar levels in people with diabetes to see how safe and effective it is.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 10 (estimated)
• Ages: 21 Years to 75 Years
• Sex: All
• Sponsor: Glucotrack (industry)
• Locations: 1 site (São Paulo, Brazil)
• Trial ID: NCT06764069 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to assess the safety and performance of an implantable continuous blood glucose monitoring system in individuals with Diabetes Mellitus. Participants will undergo a surgical procedure to insert the Sensor Lead, followed by a 96-hour observation period in the hospital where glucose levels will be monitored closely. The study will track any adverse events related to the device and evaluate its effectiveness in capturing glucose data during this time. A follow-up visit will occur one week after the device removal to ensure participant safety.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 21 to 75 with type 1 or type 2 diabetes who are on intensive insulin therapy.

Not a fit: Patients who do not have diabetes or those with poorly controlled diabetes (HbA1c ≥ 9.0%) may not benefit from this study.

Why it matters

Potential benefit: If successful, this device could provide a safer and more effective way for diabetes patients to monitor their blood glucose levels continuously.

How similar studies have performed: Previous studies on continuous glucose monitoring systems have shown promise, indicating that this approach is not entirely novel but still holds potential for significant advancements.

Eligibility criteria

Inclusion Criteria:

1. Age 21 to 75 years old inclusive
2. Generally, in good health, as determined by the investigator
3. Clinical diagnosis or type 1 or type 2 diabetes as determined via medical records or source documentation by an individual qualified to make a medical diagnosis
4. Intensive Insulin Therapy - 3 plus injections/day (MDI) or Continuous Subcutaneous Insulin Infusion (CSII)
5. HbA1c \<9.0 % in the last 3 months.
6. Study subject has adequate venous access as assessed by investigator or appropriate staff.
7. Willing to comply with study procedures and be admitted to hospital for up to 5 days.
8. Willing to perform up to 7 blood glucose (fingerstick) measurements a day using provided blood glucose meters and strips
9. Willing to wear subcutaneous continuous wear glucose sensor for the duration of the study
10. Willing to always carry study provided Android Phone during study
11. Access to internet for required periodic uploads of study device data
12. BMI in the range 18-35 kg/m2
13. Has the ability to understand and comply with protocol procedures and to provide informed consent (i.e., proficient in both verbal and written communication in English or from a translator (Portuguese to English).

Exclusion Criteria:

1. Currently taking Acetaminophen and unable to switch to another anti-inflammatory or pain reliever
2. Currently being treated with an anticoagulation agent
3. History of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or blood clotting disorder that in the opinion of the Investigator would compromise safety of the study subject.
4. Currently using one of the following non-insulin glucose-lowering agent, SGLT2 and Insulin Secretagogues
5. Female study subject of childbearing potential and has a positive pregnancy screening test
6. Female study subject of childbearing potential who is planning to become pregnant or not using adequate method of contraception deemed reliable by Investigator
7. 1 of more episodes of hypoglycemia or diabetic ketoacidosis (DKA) in the last 6 months requiring care in a medical facility or assistance from another individual to treat.
8. Study subject has a hematocrit (Hct) lower than the normal reference range
9. Known cardiovascular disease considered to be clinically relevant by the investigator
10. Currently undergoing treatment with:

    * Systemic oral or intravenous corticosteroids (current or within the last 8 weeks from screening),
    * Thyroid hormones, unless use has been stable during the past 3 months
11. Significant history of any of the following, that in the opinion of the investigator would compromise safety or successful study participation:

    * Alcoholism
    * Drug abuse
12. Significant acute or chronic illness, that in the opinion of the investigator might interfere with safety or integrity of study results
13. Current participation in another clinical drug or device study
14. Study subject may not be on the research staff of those performing this study.

Where this trial is running

São Paulo, Brazil

• Instituto do Coração (InCor) | — São Paulo, Brazil, Brazil (RECRUITING)

Study contacts

• Study coordinator: Sandra L Martha

Conditions: Diabetes Mellitus, diabetes, CBGM, CGM, type 2 diabetes, type 1 diabetes, diabetes mellitus, insulin dependent